Request Deal Involvement

Mubadala Capital and Exor Ventures led a $50m Series B round extension in Iambic Therapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Glashow Strategic Communications

pr advisors

Glashow Strategic Communications

A&O Shearman

legal advisors

A&O Shearman

or

Principals

IAMBIC THERAPEUTICS

target

IAMBIC THERAPEUTICS

MUBADALA CAPITAL

bidder

MUBADALA CAPITAL

EXOR VENTURES

bidder

EXOR VENTURES

QATAR INVESTMENT AUTHORITY

bidder

QATAR INVESTMENT AUTHORITY

ABINGWORTH MANAGEMENT

bidder

ABINGWORTH MANAGEMENT

ILLUMINA VENTURES

bidder

ILLUMINA VENTURES

NEXUS VENTURE PARTNERS

bidder

NEXUS VENTURE PARTNERS

COATUE MANAGEMENT LLC

bidder

COATUE MANAGEMENT LLC

TAO CAPITAL PARTNERS

bidder

TAO CAPITAL PARTNERS

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Mubadala Capital and Exor Ventures led a $50m Series B round extension in Iambic Therapeutics.